Overview
Renal cell carcinoma (RCC) is a common lethal disease of the urinary system. According to BMJ Best Practice, approximately 65% of patients with renal cell carcinoma present with localized tumors that are clinically curable by partial or radical nephrectomy. The remaining patients present with metastatic renal cell carcinoma, which is incurable by surgical resection and often requires systemic therapy. Renal cell carcinoma is known as the most lethal tumor of the urinary system, accounting for approximately 2% of cancer deaths worldwide. Surgical cure rates for patients with early-stage or localized disease exceed 90%; 5-year survival rates for patients with locally advanced renal cell carcinoma range from 40% to 60%. In some patients with small renal masses, surveillance and/or biopsy may be the most appropriate strategy.
Epidemiology
The global incidence of renal cancer is increasing year by year. In 2016, the global incidence of renal cancer reached 384,000, and in 2020, it will reach 431,000, with a compound annual growth rate of 3.0%. It is expected to grow at a compound annual growth rate of 2.0% from 2020 to 2025, and the number of cases will reach 476,000 in 2025; by 2030, the number of cases will reach 520,000, with a compound annual growth rate of 1.8%.
Kidney cancer is a low-incidence tumor type in China, but China has a large population base, and the incidence of kidney cancer ranks first in the world. The incidence of kidney cancer in China increased from 67,000 in 2016 to 74,000 in 2020, with a compound annual growth rate of 2.4%. It is estimated that by 2025, the incidence of kidney cancer in China will be 83,000, with a compound annual growth rate of 2.5%; by 2030, the number of kidney cancer patients in China will reach 92,000, with a compound annual growth rate of 2.1%.
Overview of Clear Cell Renal Cell Carcinoma (ccRCC)
Renal cell carcinoma (RCC) is a malignant tumor originating from the renal tubular epithelium, accounting for 80% to 90% of renal malignant tumors. Clear cell carcinoma renal cell carcinoma is also the most common pathological subtype of renal cancer, accounting for about 60% to 85% of renal cancers according to the standard of diagnosis and treatment of renal cancer issued by the National Health Commission in 2018. Clear cell renal cell carcinoma is a cortical tumor of the kidney characterized by malignant epithelial cells with clear cytoplasm and a pattern of pore-alveolar (nested) or adenosine growths interspersed with a complex stray vasculature. Clear cell renal cell carcinoma has the worst prognosis of all renal cell carcinoma pathological types and the highest potential for recurrence and metastasis.
China Clear Cell Renal Cell Carcinoma (ccRCC) Drug Market Size and Future Forecast (2016-2030E)
China’s clear cell renal cell carcinoma (ccRCC) drug market has grown year by year, from RMB 970 million in 2016 to RMB 1.72 billion in 2020, with a compound annual growth rate of 15.3%. It is estimated that by 2025, with a compound annual growth rate of 21.2%, the market size of clear cell renal cell carcinoma (ccRCC) drugs in China will reach RMB 4.49 billion, and will further grow at a compound annual growth rate of 11.8%. It will reach RMB 7.86 billion in 2030.
To view the full report click here
Note: The articles on this site have not been posted and shared by netizens or institutions unless they are marked as original. If there is any need for publicity or infringement, please contact [email protected].
This article is reprinted from: https://www.dx2025.com/archives/166584.html
This site is for inclusion only, and the copyright belongs to the original author.